Here's How Trump's Drug Deals Are Likely to Impact Healthcare ETFs
President Trump announced expanded Most-Favoured-Nation (MFN) drug pricing agreements with 26 pharmaceutical companies, covering 89% of the branded drug market. The deals include nine additional firms alongside previous agreements with major drugmakers. While lower drug prices may benefit healthcare providers and insurers, the impact on pharmaceutical companies is mixed, with agreements primarily targeting Medicaid and government-sponsored plans rather than employer-sponsored insurance.